The Norton Lab will collaborate with Biotech company Q-Vant Biosciences to develop a new oral vaccine platform for prevention of multiple infectious diseases. The platform will combine adjuvants developed by Tulane and Q-Vant to help facilitate a stronger immune response to orally delivered vaccines.
See the news article published by Tulane to learn more:
https://news.tulane.edu/news/tulane-university-awarded-92-million-nih-contract-innovative-oral-vaccine-development